Radiation Research
Return to Library
|
Free Radiation Research Articles |
|
|
|
|
Research on life sciences discussed by scientists at Department of Energy
2009 AUG 10 - (NewsRx.com) -- Investigators publish new data in the report 'History and development of radiation-protective agents.' According to recent research from the United States, "The search for ideal protective agents for use in a variety of radiation scenarios has continued for more than six decades. This review evaluates agents and procedures that have the potential to protect against acute and late effects of ionising radiation when administered either before or after radiation exposure." "Over the years, extensive experimental studies of radiation-protective agents have enhanced our knowledge of radiation physics, chemistry, and biology. However, translation of agents from animal testing to use in various scenarios, such as prophylactic adjuncts in radiotherapy or post-exposure treatments for potential victims of radiation accidents/incidents, has been slow. Nevertheless, a number of compounds are now available for use in a variety of radiation situations. These include agents approved by the U.S. Food and Drug Administration for use in reducing exposure to internal radionuclides (Prussian blue, calcium diethylenetriamene pentaacetate (DTPA) and zinc DTPA, potassium iodide) and amifostine for alleviating xerostomia associated with radiotherapy. Consensus groups have also recommended other therapies such as granulocyte colony-stimulating factor for radiation-induced neutropenia. The variety of prophylactic and therapeutic agents in the research pipeline includes those that are naturally-occurring with low toxicity, provide a long window of protection, protect normal tissue while sensitising tumours, or act via receptors and modulate biological processes such as induction of genes responsible for radioresistance," wrote J.F. Weiss and colleagues, Department of Energy. The researchers concluded: "The search for agents that protect against acute and late effects of ionising radiation injury will undoubtedly continue into the future and influence other areas of radiation research." Weiss and colleagues published their study in International Journal of Radiation Biology (History and development of radiation-protective agents. International Journal of Radiation Biology, 2009;85(7):539-73). For additional information, contact J.F. Weiss, Office of Health and Safety, United States Dept. of Energy, Washington, DC USA.. Publisher contact information for the International Journal of Radiation Biology is: Taylor & Francis Group Ltd, 2 Park Square, Milton Park, Abingdon, Oxford OX14 4RN United Kingdom. Keywords: United States, Washington, Life Sciences, Regulatory Actions, Treatment, Therapy. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2009, Biotech Business Week via NewsRx.com.
|
